Clinically significant responses achieved with romidepsin across disease compartments in patients with cutaneous T-cell lymphoma

Leukemia and Lymphoma

Volumn 56, Issue 10, 2015, Pages 2847-2854

  Kim, Ellen J ^a   Kim, Youn H ^b   Rook, Alain H ^a   Lerner, Adam ^c   Duvic, Madeleine ^d   Reddy, Sunil ^b   Robak, Tadeusz ^e   Becker, Jürgen C ^f   Samtsov, Alexey ^g   McCulloch, William ^h   Waksman, Joel ⁱ   Whittaker, Sean ^j  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b STANFORD CANCER INSTITUTE   (United States)

^c BOSTON MEDICAL CENTER   (United States)

^d UNIVERSITY OF TEXAS   (United States)

^e MEDICAL UNIVERSITY OF LODZ   (Poland)

^f MEDICAL UNIVERSITY OF GRAZ   (Austria)

^g S M KIROV MILITARY MEDICAL ACADEMY   (Russian Federation)

^h Alba BioPharm Advisors Inc   (United States)

ⁱ Brightech International LLC   (United States)

^j GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

more..

Author keywords

Lymphoma and Hodgkin disease; pharmacotherapeutics; prognostication

Indexed keywords

ROMIDEPSIN; ANTINEOPLASTIC ANTIBIOTIC; DEPSIPEPTIDE;

ADULT; AGEUSIA; ANEMIA; ANOREXIA; ARTICLE; CANCER CHEMOTHERAPY; CANCER STAGING; CUTANEOUS T CELL LYMPHOMA; DIARRHEA; DISEASE ASSESSMENT; DRUG EFFICACY; DRUG SAFETY; DYSGEUSIA; ENZYME ACTIVITY; ERYTHRODERMA; FEMALE; FOOD AND DRUG ADMINISTRATION; HEADACHE; HUMAN; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAUSEA; OPEN STUDY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; SINGLE BLIND PROCEDURE; SYSTEMIC THERAPY; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING; CANCER GRADING; CLINICAL TRIAL; LYMPHOMA, T-CELL, CUTANEOUS; PATHOLOGY; PHASE 2 CLINICAL TRIAL; RETREATMENT; TUMOR VOLUME;

ANTIBIOTICS, ANTINEOPLASTIC; DEPSIPEPTIDES; FEMALE; HUMANS; LYMPHOMA, T-CELL, CUTANEOUS; MALE; NEOPLASM GRADING; NEOPLASM STAGING; RETREATMENT; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84947585232     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2015.1014360     Document Type: Article

References (35)

1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005;105:3768-3785.
2. Agar NS, Wedgeworth E, Crichton S, et al. Survival outcomes and prognostic factors in mycosis fungoides/sezary syndrome: validation of the revised International Society for Cutaneous Lymphomas/European Organisation for Research and Treatment of Cancer staging proposal. J Clin Oncol 2010;28:4730-4739.
3. Criscione VD, Weinstock MA. Incidence of cutaneous T-cell lymphoma in the United States, 1973-2002. Arch Dermatol 2007;143:854-859.
4. Korgavkar K, Xiong M, Weinstock M. Changing incidence trends of cutaneous T-cell lymphoma. JAMA Dermatol 2013;149:1295-1299.
5. NCCN clinical practice guidelines in oncology: Non-Hodgkin's lymphoma. V. 2. 2015. Available from: nccn. org
6. Olsen E, Vonderheid E, Pimpinelli N, et al. Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the Cutaneous Lymphoma Task Force of the European Organization of Research and Treatment of Cancer (EORTC). Blood 2007;110:1713-1722.
7. Klemke CD, Mansmann U, Poenitz N, et al. Prognostic factors and prediction of prognosis by the CTCL severity index in mycosis fungoides and Sezary syndrome. Br J Dermatol 2005;153: 118-124.
8. Talpur R, Singh L, Daulat S, et al. Long-term outcomes of 1,263 patients with mycosis fungoides and Sezary syndrome from 1982 to 2009. Clin Cancer Res 2012;18:5051-5060.
9. Parker SR, Bradley B. Treatment of cutaneous T-cell lymphoma/mycosis fungoides. Dermatol Nurs 2006;18:566-570, 573-575.
10. Demierre M. Mycosis fungoides and Sezary syndrome: The burden of pruritus. Community Oncol 2010;7:399-403.
11. Ahern K, Gilmore ES, Poligone B. Pruritus in cutaneous T-cell lymphoma: a review. J Am Acad Dermatol 2012;67:760-768.
12. Demierre MF, Gan S, Jones J, et al. Significant impact of cutaneous T-cell lymphoma on patients' quality of life: results of a 2005 national Cutaneous Lymphoma Foundation survey. Cancer 2006;107:2504-2511.
13. Vij A, Duvic M. Prevalence and severity of pruritus in cutaneous T cell lymphoma. Int J Dermatol 2012;51:930-934.
14. Olsen EA, Whittaker S, Kim YH, et al. Clinical end points and response criteria in mycosis fungoides and Sezary syndrome: a consensus statement of the International Society for Cutaneous Lymphomas, the United States Cutaneous Lymphoma Consortium, and the Cutaneous Lymphoma Task Force of the European Organisation for Research and Treatment of Cancer. J Clin Oncol 2011;29:2598-2607.
15. Targretin (bexarotene) [package insert]. Bridgewater, NJ: Valeant Pharmaceuticals North America LLC; 2013.
16. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19:2456-2471.
17. Ontak (denileukin diftitox) [package insert]. Woodcliff Lake, NJ: Eisai Inc.; 2008.
18. Olsen E, Duvic M, Frankel A, et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001;19:376-388.
19. ISTODAX (romidepsin) [package insert]. Summit, NJ: Celgene Corporation; 2014.
20. Whittaker S, Demierre M, Kim EJ, et al. Final results from a multicenter, international, pivotal study of romidepsin in refractory cutaneous T-cell lymphoma. J Clin Oncol 2010;28:4485-4491.
21. Zolinza (vorinostat) [package insert]. Whitehouse Station, NJ: Merck & Co., Inc.; 2013.
22. Duvic M, Talpur R, Ni X, et al. Phase 2 trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) for refractory cutaneous T-cell lymphoma (CTCL). Blood 2007;109:31-39.
23. Tan J, Cang S, Ma Y, et al. Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. J Hematol Oncol 2010;3:5.
24. Bolden JE, Peart MJ, Johnstone RW. Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 2006;5: 769-784.
25. Bradner JE, West N, Grachan ML, et al. Chemical phylogenetics of histone deacetylases. Nat Chem Biol 2010;6:238-243.
26. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol 2009;27: 5410-5417.
27. Kim YH, Demierre MF, Kim EJ, et al. Clinically meaningful reduction in pruritus in patients with cutaneous T-cell lymphoma treated with romidepsin. Leuk Lymphoma 2013;54:284-289.
28. American Joint Committee on Cancer. Lymphoid neoplasms. In: Green FL Page DL, Fleming ID, et al., editors. AJCC cancer staging manual. 6th ed. New York, NY: Springer; 2002. pp 391-406.
29. Bunn PA Jr, Lamberg SI. Report of the Committee on Staging and Classification of Cutaneous T-Cell Lymphomas. Cancer Treat Rep 1979;63:725-728.
30. Stevens SR, Ke MS, Parry EJ, et al. Quantifying skin disease burden in mycosis fungoides-type cutaneous T-cell lymphomas: The severity-weighted assessment tool (SWAT). Arch Dermatol 2002;138: 42-48.
31. Heald P. Clinical trials and efficacy assessment in the therapy of cutaneous T cell lymphoma. Ann NY Acad Sci 2001;941:155-165.
32. Edelson R, Berger C, Gasparro F, et al. Treatment of cutaneous T-cell lymphoma by extracorporeal photochemotherapy. Preliminary results. N Engl J Med 1987;316:297-303.
33. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000;92:205-216.
34. Lundin J, Hagberg H, Repp R, et al. Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003;101:4267-4272.
35. Olsen EA, Kim YH, Kuzel TM, et al. Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25: 3109-3115.